Navigation Links
BioSpecifics Technologies Corp. Announces Presentations at Two Upcoming Investor Conferences in March
Date:2/29/2012

LYNBROOK, N.Y., Feb. 29, 2012 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX® in the U.S. and XIAPEX® in Europe and Eurasia, today announced that BioSpecifics' President, Tom Wegman, will present at the following upcoming investor conferences during the month of March 2012.

  • Cowen and Company 32nd Annual Health Care Conference (Boston, MA)
    Wednesday, March 7, 2012 at 10:40 a.m. EST
  • ROTH Capital Partners 24th Annual Conference (Laguna Niguel, CA)
    Tuesday, March 13, 2012 at 3:30 p.m. PDT (6:30 p.m. EDT)

The live webcasts of these presentations can be accessed under "Calendar of Events" in the Investor Relations section of the Company's website at www.biospecifics.com.

About BioSpecifics Technologies Corp.

BioSpecifics Technologies Corp. is a biopharmaceutical company that has developed injectable collagenase for twelve clinical indications. Its partner Auxilium Pharmaceuticals, Inc. markets XIAFLEX® in the U.S. for the treatment of Dupuytren's contracture in adults with a palpable cord in the palm and is also developing XIAFLEX for the treatment of Peyronie's disease, which is currently in Phase 3 pivotal clinical trials, as well as for Frozen Shoulder (Adhesive Capsulitis) and cellulite which are in Phase 2 and Phase 1 respectively. Pfizer, Inc. is responsible for marketing XIAPEX® for Dupuytren's contracture in the 27 European Union member countries and 19 other European and Eurasian countries and also has commercialization and development rights for Peyronie's disease in these same territories. Asahi Kasei Pharma Corporation has development and commercial rights for XIAFLEX for Dupuytren's c
'/>"/>

SOURCE BioSpecifics Technologies Corp.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. BioSpecifics Technologies Corp. Announces Appointment of George Gould to Board of Directors
2. BioSpecifics Technologies Corp. to Host Conference Call to Report Third Quarter 2011 Financial Results on November 8, 2011
3. BioSpecifics Technologies Corp. Announces Data Presentations at Upcoming XVI Annual Federation of the European Societies for Surgery of the Hand Meeting
4. BioSpecifics Technologies Corp. Reports First Quarter 2011 Financial Results
5. BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2010 Financial Results
6. BioSpecifics Technologies Corp. to Host Conference Call to Report Fourth Quarter and Full Year 2010 Financial Results on March 11, 2011
7. BioSpecifics Technologies Corp. to Present at Cowen and Company 31st Annual Health Care Conference
8. BioSpecifics Announces Positive Results From Clinical Trial in Canine Lipomas
9. BioSpecifics Technologies Corp. to Present at UBS Global Life Sciences Conference
10. BioSpecifics Technologies Corp. to Present at Rodman & Renshaw 12th Annual Healthcare Conference
11. Reissue with Tables: BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... (PRWEB) May 22, 2015 Knowledgent ... white paper that explores the potential of big data ... white paper was developed to help life sciences and ... leverage data to gain critical business insights. , The ... amounts of data driven by patient profiling, compliance and ...
(Date:5/21/2015)... , May 21, 2015  Susan Hedstrom, ... (FPWR), a nonprofit organization dedicated to supporting research ... syndrome (PWS), announced today that FPWR has received ... Irina Shaulov contributed $1 million in ... initiatives.  "Our ...
(Date:5/21/2015)... May 21, 2015 W. R. ... manufacturing facility in Worms, Germany has received good ... subsidiary of the International Pharmaceutical Excipient Council (IPEC) ... that produce its SYLOID® FP brand of pharmaceutical ... certification, following the Curtis Bay, Maryland (USA) and ...
(Date:5/21/2015)... May 21, 2015 /PRNewswire/ - RepliCel Life Sciences ... regenerative medicine company focused on the development of ... presentation at the International Society for Cellular Therapy ... Achilles tendinosis currently in a Phase 1/2 clinical ... th from 5:30 PM to 7:00 PM ...
Breaking Biology Technology:New White Paper Explores the Potential of Big Data Analytics in Life Sciences and Healthcare 2The Foundation for Prader-Willi Research Receives $1M Contribution in Support of Clinical Initiatives 2Grace European Facility Receives GMP Excipient Certification for SYLOID® FP Silica Gel 2RepliCel to Present Unique Autologous Cell Treatment for Achilles Tendinosis at International Society for Cellular Therapy Conference 2RepliCel to Present Unique Autologous Cell Treatment for Achilles Tendinosis at International Society for Cellular Therapy Conference 3
... In an address to,shareholders at the company,s annual ... Chairman and CEO David B. Snow Jr. today ... to deliver strong,continuing earnings growth through 2008 and ... pharmacy to retaining and winning,customers, and advanced clinical ...
... Detects Extravasations during CT ... Contrast ... today,that its XDS(TM) Extravasation Detector has received a 2008 Medical ... in the,detection of leaking intravenous contrast media from the injection ...
... 22 Nektar,Therapeutics (Nasdaq: NKTR ) announced ... Company as Chief Operating Officer and Head of ... all aspects of the PEGylation Business Unit, including ... Company. He will also,serve as Chairman of Nektar ...
Cached Biology Technology:Medco CEO to Shareholders: Delivering Results, Driving Shareholder Value 2Medco CEO to Shareholders: Delivering Results, Driving Shareholder Value 3Medco CEO to Shareholders: Delivering Results, Driving Shareholder Value 4MEDRAD(R) XDS(TM) Extravasation Detector Wins Medical Design Excellence Award 2MEDRAD(R) XDS(TM) Extravasation Detector Wins Medical Design Excellence Award 3Bharatt Chowrira Joins Nektar Therapeutics as Chief Operating Officer and Head of PEGylation Business Unit 2Bharatt Chowrira Joins Nektar Therapeutics as Chief Operating Officer and Head of PEGylation Business Unit 3
(Date:5/11/2015)... , May 11, 2015 Curemark LLC, a ... start of a new Phase III double blind, randomized, ... novel formulation, CM-AT, on all children ages 3-8 with ... FDA Phase III double blinded clinical trial for CM-AT ... levels of the digestive enzyme chymotrypsin. This new trial ...
(Date:5/6/2015)... AVIV, Israel , May 6, 2015 ... world,s most established helmet producer, announced today that they ... Smart Helmet, the world,s first bio-sensing cycling helmet and ... be released in two new colors in order to ... for the product. In addition, LifeBEAM and Lazer announced ...
(Date:4/27/2015)... Fla. , Apr. 27, 2015 Profile ... access control and security systems is pleased to announce ... company as a consultant and member of its scientific ... is widely known as a thought leader in technology-enhanced ... Learning Technology Group, and has published studies and books ...
Breaking Biology News(10 mins):Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 2LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 2Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 4
... Emory University School of Medicine have obtained a detailed ... key immune system genes. The finding could help ... drugs with fewer side effects. The results are ... Nature Structural & Molecular Biology . Synthetic ...
... du Sud, 7 décembre 2012 Integrated Biometrics, ... technologique grâce à la certification par le FBI ... développement d,IB a créé un nouveau produit en ... Sensor (LES) ainsi qu,à un transistor en couches ...
... humans interbreed and produce offspring of mixed ancestry? ... with anatomically modern humans tens of thousands of years ... human gene pool. But the findings are not universally ... clarify the role of interbreeding, which is also known ...
Cached Biology News:Steroid hormone receptor prefers working alone to shut off immune system genes 2Integrated Biometrics présente Sherlock, le capteur d'empreintes digitales le plus léger, le plus mince et le plus petit, certifié conformément à l'Annexe F Mobile ID 2Monkey business: What howler monkeys can tell us about the role of interbreeding in human evolution 2Monkey business: What howler monkeys can tell us about the role of interbreeding in human evolution 3
... 0.1 mL - 25 mL pipets ,Angled acrylic ... most standard square or round pipet cans. Constructed of ... each 76 mm W x 76 mm H x ... ins.). Overall dimensions: 89 mm W x 406 mm ...
... contains choice of PDMS Stamps (3 PDMS ... 200 micron squares or 100 um x ... mm lines, 3 PDMS nano-patterned stamps with ... and pitch of 400 nm, or 3 ...
Request Info...
RECOMBINANT EQUINE IL-4 Product Type: Recombinant Protein...
Biology Products: